|
|
Article: Griffin Securities Announces Investment Opinion on Targeting Cancer Stem Cells.
- Article from:
- Business Wire
- Article date:
- October 9, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Stem Cell Hypothesis Offers Rational Approach to Preventing, Diagnosing, and Treating Malignant Growth
NEW YORK -- Griffin Securities ("Griffin"), a research-driven investment banking firm, has released an industry report on the subject of targeting cancer stem cells (CSCs). The stem cell hypothesis offers a rational approach to preventing, diagnosing, and treating malignant growth. Covered in the report are five classes of drugs nearing the Phase II clinical trial that provides human proof-of concept data, a crucial stage of development: Notch signaling, P13k/akt pathway, immunotherapeutics, molecular chaperons, and hedgehog signaling.
Companies ...
Related newspaper, magazine, and journal articles:
|
|
Article: Griffin Securities, Inc. Announces Investment ...
Business Wire;
April 6, 2006 ;
405 words
...NEW YORK -- Griffin Securities initiated research coverage ... Research, issued the report. Griffin Securities, Inc., is a New York City ... including disclosures, contact: Griffin Securities, Inc. Chrystyna Bedrij ...
|
|